ART

Two drugs dolutegravir-lamivudine would be cost-effective and would achieve ample financial savings and facilitate adherence

Claudio Souza
First-line anti-retroviral virologic suppression using a drug regimen of dolutegravir (Tivicay) and lamivudine would be highly cost-effective and could save about $ 500 million in healthcare systems over the course of

Cabotegravir + rilpivirine in Long Injectable Formulation Duration Kill Viral Suppression by 32 weeks

Claudio Souza
David Margolis at CROI 2014 (Photo: Liz Highleyman) The combination of two long-acting injectable antiretroviral drugs - ViiV Healthcare's experimental cabotegravir integrase inhibitor

This Site uses Cookies and you may refuse this use. But you may well know what is being recorded in consonance with our política the privatization cidade